On June 10, LG Chem held the 20th LG Growth Study (LGS) Symposium, targeting pediatric endocrinologists, during which it disclosed interim findings from a long-term observational study of its growth hormone, Yeutropin.
The presentation primarily focused on safety data after 12 years of treatment and efficacy results at the 4-year mark.
Since launching the LGS project in 2012, LG Chem has been collecting long-term growth hormone therapy data on Korean children with short stature, making it the first initiative of its kind in South Korea. The ongoing study aims to recruit 10,000 children with growth deficits by 2027 and track the safety and efficacy of Yeutropin until 2035. As of 2024, approximately 7,000 patients have been registered.
During the symposium, Professor Hong Yong-hee from Soonchunhyang University Bucheon Hospital highlighted positive growth outcomes in treated children. He explained, “Children with growth hormone deficiency and those born with low birth weight showed significant height improvements after treatment. Before therapy, their average height standard deviation score (SDS) was -2.5, but after 48 months, it improved to -0.9.” He also noted that children with idiopathic short stature experienced meaningful progress, with SDS improving from -2.5 to -1.1. The closer the SDS is to zero, the closer their height is to the average for their age.
Additionally, Professor Lee Hae-sang from Ajou University Hospital presented a separate analysis of children with low birth weight registered in the LGS study, emphasizing that Yeutropin demonstrated sustained safety and efficacy as a long-term treatment option.
Son Ji-woong, Head of the Life Sciences Business Division at LG Chem, stated, “LGS will become the largest-scale database for growth hormone therapy practically applicable to Korean children with short stature. Moving forward, we will continue to support research on short stature and provide optimal treatment solutions for these patients.”
